Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · April 21, 2022

Radiotherapy Plus Nivolumab or Temozolomide for Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma

Neuro-Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Neuro-Oncology
Radiotherapy Combined With Nivolumab or Temozolomide for Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter: An International Randomized Phase 3 Trial
Neuro-oncology 2022 Apr 14;[EPub Ahead of Print], A Omuro, AA Brandes, AF Carpentier, A Idbaih, DA Reardon, T Cloughesy, A Sumrall, J Baehring, M van den Bent, O Bähr, G Lombardi, P Mulholland, G Tabatabai, U Lassen, JM Sepulveda, M Khasraw, E Vauleon, Y Muragaki, AM Di Giacomo, N Butowski, P Roth, X Qian, AZ Fu, Y Liu, V Potter, AG Chalamandaris, K Tatsuoka, M Lim, M Weller

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Brain Cancer Center of Excellence

Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.


Further Reading